DECLARE-DIABETES Trial Design
The lesions Suitable for PCI in patients with DM
SES (200 patients)
1:1 randomization
PES (200 patients)
Triple group Standard group
Angiographic and IVUS follow-up at 6 months Clinical follow-up at 30 days and 9 months 1:1 randomization
* Randomization -Stratification according to DES types * Blinding -Patients, Outcome assessors * Pre-specified angiographic primary endpoint * Intention-to-treat analysis
Triple antiplatelet group, n=200
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Lee SW, Park SW et al. J Am Coll Cardiol March, 2008; 51:1181-7 In-segment In-stent • Although DES has reduced angiogrpahic restenosis and improved long-term outcomes compared with BMS implantation in patients with DM or complex lesions subsets, the diabetics or the patients with long lesions have a higher adverse cardiac outcomes after DES implantation
• We previously performed randomized, multicenter, prospective study showing triple antiplatelet therapy for 6 or 8 months in patients with DM (DECLARE-DIABETES trial) or long lesions (DECLARE-LONG I and II trials) was superior to dual antiplatelet therapy in reducing angiographic restenosis.
Background
• However, the primary endpoint of each DECLARE trial (DECLARE-DIABETES, DECLARE-LONG I and II) was late loss using small sample size.
• So, we want to evaluate the impact of triple antiplatelet therapy on angiographic restenosis after DES implantation and to find the predictor of angiographic restenosis • Triple antiplatelet therapy reduced late loss by 0.12 mm and restenosis by 40%.
• Impact of triple antiplatelet therapy on angiographic restenosis was most prominent in Cypher stent, compared with Taxus and Endeavor, which translated to very low restenosis rate (0.5%) in SES with low late loss.
Conclusions
